Amgen, Cytokinetics start early-stage study of oral heart drug

Cytokinetics Inc. and Amgen Inc. started an early-stage study of the oral form of a cardiac muscle-activating drug.
An intravenous formulation of the drug, called omecamtiv mecarbil, already is in a nearly 600-patient Phase IIb trial by Amgen (NYSE: AMGN).